Effect of US Drug Enforcement Administration’s Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing
Christopher M. Jones(Substance Abuse and Mental Health Services Administration), Douglas C. Throckmorton(United States Food and Drug Administration), Peter Lurie(Center for Science in the Public Interest (United States))
Cited by 127
Related Papers
Trends in US Emergency Department Visits for Mental Health, Overdose, and Violence Outcomes Before and During the COVID-19 Pandemic
|JAMA Psychiatry|2021|594
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
|Nature Biotechnology|2010|406
PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products
|Kidney International|1995|174
Activation-induced apoptosis in human macrophages: developmental regulation of a novel cell death pathway by macrophage colony-stimulating factor and interferon gamma.
|The Journal of Experimental Medicine|1995|172